Author(s)

Rhian Bakker

Affiliation(s)

Philips, Monroeville, PA, USA.

Corresponding Author

Rhian Bakker

ABSTRACT

Multiple myeloma (MM) is a malignant plasma cell tumor that is still an incurable disease. In recent years, adoptive cell therapy (ACT) has developed rapidly in hematological tumors. This article mainly reviews the application progress from bone marrow infiltrating lymphocytes to genetically modified T cells to NK cells in MM. In general, ACT therapy for multiple myeloma is gradually developing towards high specificity and strong lethality. However, finding specific target antigens and preventing toxic effects of treatment are still two major problems for ACT.

KEYWORDS

Hematology; Multiple myeloma; Adoptive cell therapy; Bone marrow infiltrating lymphocytes; CAR-T cells; TCR-T cells; CAT-NK cells

CITE THIS PAPER

Rhian Bakker. Advances in adoptive cellular immunotherapy in multiple myeloma. World Journal of Clinical Sciences. 2024, 2(1): 8-11. DOI: 10.61784/wjcs240155.

REFERENCES

[1] ROLLIG C, KNOP S, BORNHAUSER M. Multiple m yeloma. Lancet, 2015, 385(9983): 2197-2208.

[2] GAHRTON G, TOUR S, HEATHER MAN P. Prognosticfactorsinallog eneicbone marrow transplant formulatip lemyeloma. Journal of Clinical On-colo gy, 1995, 13(6): 1312-1322.

[3] TRICOT G, VESOLE D H, JAGANNATH S. Graft-versus-myeloma effect: p roof of p rincip le. Blood, 1996, 87(3): 1196-1198.

[4] NOONAN K A, HUFF C A, DAVIS J. Adoptivetransferofactivated marrow-infiltrating l ym-p hocytes inducesmeasurableantitumorimmunity inthe bone marrow inmultip lemyeloma. ScienceTransla-tionalMedicine, 2015, 7(288): 288ra78.

[5] GARFALL AL, MAUS MV, HWANG WT Chimeric antigenreceptorT cells againstCD19formula-of p lemyeloma. TheNew EnglandJournal of Medicine, 2015, 373(11): 1040.

[6] GRUPP S A, KALOS M, BARRETT D. Chimericantigen receptor-modified T cells for acute l ym p hoidleukemia. The New EnglandJournalof Medicine, 2013, 368(16): 1509-1518.

[7] FAN F, ZHAO W, LIUJ. Durable remissions withBCMA-specificchimericantigen receptor (CAR)-modified T cells in p atients with refractory/relap sed multip le myeloma. JournalofClinical Oncology, 2017, 35(18 suppl): LBA3001.

[8] RAMOS C A, SAVOLDO B, B, TORRANO V Clinical responseswith T lymphocytes targeting malignancy-associatedkappa lightchains. TheJournalof ClinicalInvestigation, 2016, 126(7): 2588.

[9] RASCHE L, WEINHOLD N, MORGAN GJ. Immunologic approachesforthe treatment of multip le m yeloma. Cancer Treatment Reviews, 2017, 55: 190-199.

[10] GARGETT T, BROWN M P. Theinducible caspase-9 s uicide gene systemasa " safety switch" to limiton-tar-get, off-tumor toxicitiesofchimericantigenreceptorT cells. Frontiers inPharmacology, 2014, 5: 235.

[11] WANG X, CHANG W C, WONGC W. Atrans-gene-encodedcellsurface pol ypeptidefor selection, in vivotracking, and ablation of engineered cells. Blood, 2011, 118(5): 1255-1263.

[12] VOGLER I, NEWRZELA S, HARTMANN S. An im p roved bicistronic CD20/tCD34 vector for efficient p urificationandinvivodep letionof gene-modi-fied T cellsforadop tiveimmunotherapy. Molecular Therapy, 2010, 18(7): 1330-1338.

[13] FEDOROV VD, THEMELIM, SADELAIN M. PD-1-andCTLA-4-basedinhibitory chimericantigenreceptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine, 2013, 5 (215): 215ra172.

[14] MOOREGL, LEES H, SCHUBBERTS. Tun-ingT cellaffinity im proves efficac y andsafety ofanti-CD38 × anti-CD3bispecificantibodiesin monkeys -a potentialtherapy for multip le m yeloma. Blood, 2015, 126(23): 1798-1798.

[15] ZOU J, CHEN D, ZONG Y. Immunotherapy basedonbisp ecific T-cell engager with hIgG1 Fc sequence as a new therap eutic strategy in multip le m yeloma. CancerScience, 2015, 106(5):512-521.

[16] THAKUR A, AL-KADHIMI Z, DEOL A. In-ductionofanti-myelomacellularandhumoralimmunity b y pre-targeting clono g enicmyelomacells p rior to stem cell transplantwith T cellsarmedwithanti-CD3×anti-CD20bispecificantibody leads to transferofcellularand humoralanti-myelomaimmunity. Blood, 2013, 122 (21): 139-139.

[17] HONEMANND, KUFERP, RIMPLER MM. A novelrecombinantbisp ecificsing lechainantibody, bsc-Wue-1×CD3, induces T-c ell-mediated cytotoxicity to-wardshuman multiple myelomacells. Leukemia, 2004, 18(3): 636-644.

[18] VAN RF, SZMANIASM, ZHANF. NY-ESO-1 is highl y expressed in poor-pro gnosis multip le m yelomaandinduces spontaneous humoraland cellular immune responses. Blood, 2005, 105(10): 3939-3944.

[19] RAPOPORT A P, STADTMAUER E A, BINDER-SCHOLl G K. NY-ESO-1-specific TCR engineered T cellsmediatesustainedantigen-specific an-titumor effects in m yeloma. Nature Medicine, 2015, 21(8): 914-921.

[20] MORETTA L, LOCATELLI F, PENDE D. KillerIg-like receptor-mediatedcontrolofnaturalkiller cellalloreactivity inhap loidenticalhematopoietic stem cell transplantation. Blood, 2011, 117(3): 764-771.

[21] FROHN C, HOPPNER M, SCHLENKE P. Anti-myelomaactivity ofnaturalkillerlym p hoc ytes. BritishJournalof Haematology, 2002, 119(3): 660-664.

[22] RUGGERIL, CAPANNIM, URBANIE. Effec-tivenessofdonornaturalkillercellalloreactivity in mismatchedhematopoietic transplants. Science, 2002, 295(5562): 2097-2100.

[23] SHI J, TRICOT G, SZMANIA S. Infusionof hap lo-identical killer immunog lobulin-like receptor ligandmismatchedNKcellsforrelap sedmyelomainthe setting of autolo gous stem cell transplantation. British Journal of Haematology, 2008, 143 (5): 641-653.

[24] JIANG H, ZHANG W, SHANGP. Transfection ofchimericanti-CD138gene enhancesnaturalkillercell activationand killing of multip le myelomacells. MolecularOncology, 2014, 8(2): 297-310.

[25] CHUJ, DENG Y, BENSON D M. CS1-specific chimericantigen receptor (CAR) -engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multip le m yeloma. Leukemia, 2014, 28(4): 917-927.